Foster Group Inc. buy 713 shares of Eli Lilly and Company (NYSE:LLY)

VaselineSeptember 1, 2024

0 4 minutes read

Eli Lilly and Company logo Foster Group Inc. grew its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 43.4% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 2,354 shares of the company’s stock after acquiring an additional 713 shares during the period. Holdings held by Foster Group Inc. in Eli Lilly and Company were worth $2,132,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Everpar Advisors LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $1,845,000. International Assets Investment Management LLC raised its stake in Eli Lilly and Company by 5.3% in the fourth quarter. International Assets Investment Management LLC now owns 12,597 shares of the company’s stock worth $7,343,000 after purchasing an additional 632 shares during the period. AMJ Financial Wealth Management bought a new position in Eli Lilly and Company in the fourth quarter valued at $201,000. GUNN & Co INVESTMENT MANAGEMENT INC. lifted its position in Eli Lilly and Company by 124.7% during the fourth quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 1,438 shares of the company’s stock valued at $838,000 after buying an additional 798 shares during the period. Finally, Providence First Trust Co bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $274,000. 82.53% of shares are currently held by institutional investors.

Insider Trading at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 192,794 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $829.77, for a total transaction of $159,974,677.38. Following the sale, the insider now owns 98,208,810 shares of the company’s stock, valued at approximately $81,490,724,273.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC’s website. In related news, major shareholder Lilly Endowment Inc sold 192,794 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $829.77, for a total transaction of $159,974,677.38. Following the completion of the transaction, the insider now directly owns 98,208,810 shares of the company’s stock, valued at $81,490,724,273.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible via this hyperlink. Also, EVP Johna Norton sold 7,056 shares of Eli Lilly and Company stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the sale, the executive vice president now owns 25,428 shares in the company, valued at $20,835,194.64. The disclosure for this sale can be found here. Insiders have sold a total of 1,097,883 shares of company stock worth $972,022,568 over the last 90 days. Company insiders own 0.13% of the company’s shares.

Eli Lilly and Company stock rose 2.1%

Want more great investment ideas?

Shares of LLY stock opened at $960.02 on Friday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11, and a quick ratio of 0.87. Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53. The company’s fifty day moving average price is $892.64 and its 200 day moving average price is $821.53. The company has a market cap of $912.43 billion, a price-to-earnings ratio of 141.39, a PEG ratio of 2.91 and a beta of 0.41.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15. This represents a dividend of $5.20 on an annualized basis and a yield of 0.54%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Analysts set new price targets

A number of brokerages have issued reports on LLY. Bank of America raised their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Jefferies Financial Group upped their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Berenberg Bank upped their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Argus boosted their price objective on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th. Finally, Barclays boosted their target price on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Two research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The company currently has a consensus rating of “Moderate Buy” and an average target price of $961.76, based on data from MarketBeat.com.

Read our latest report on LLY

About Eli Lilly and Company

(Free report)

Eli Lilly and Company discovers, develops and markets human pharmaceutical products worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R and Humulin U-500 for diabetes; Jardiance, Mounjaro and Trulicity for type 2 diabetes; and Zepbound for obesity.